FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of formula I
,
where R11 is selected from the group consisting of benzylamino, N-methylbenzylamino, N-methyl(4-fluorobenzyl)amino, N-methyl(4-methoxybenzyl)amino, N-methyl(3,5-dimethoxybenzyl)amino, N-methyl(pyridine-2-yl)amino, N-methyl(pyridin-3-yl)amino, piperidino, 4-methylpiperazin-1-yl, morpholino, thiomorpholino, pyrrolidino, 3-methoxypyrrolidin-1-yl, pyrrolidin-3-ol-1-yl, 2-(2-methanol-1-yl)pyrrolid-1-yl, 2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl, 2-(2-propanol-2-yl)pyrrolidin-1-yl, isoindolin-2-yl, 4-(pyrrolidin-1-yl)piperidin-1-yl, N,N-diethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-ethynylamino, N-(thiazol-2-ylmethyl)-N-methylamino, azetidin-1-yl, 3-methyl-3-ol-azetidin-1-yl, 3-(ethanol-2-yl)azetidin-1-yl, 3-methoxyazetidin-1-yl, 3-hydroxyazetidin-1-yl, 3-ethoxyazetidin-1-yl, 3-isopropoxyazetidin-1-yl, 3-(2-propanol-2-yl)azetidin-1-yl, 3-(morpholinomethyl)azetidin-1-yl, 3-morpholinoazetidin-1-yl, 3-(pyrrolidin-1-yl)azetidin-1-yl, 3-(pyrrolidin-1-ylmethyl)azetidin-1-yl, 3-(1-methoxyethyl)azetidin-1-yl, N-(3-(N,N-dimethylamino)propyl)-N-methylamino and 4-(N,N-dimethylamino)piperidin-1-yl; R13 is selected from the group consisting of 3-(ethanol-1-yl)phenyl, 3-(1-ol-2,2,2-trifluoroethan-1-yl)phenyl, 2-(1-ol-2,2,2-trifluoroethan-1-yl)phenyl, 4-(1-ol-2,2,2-trifluoroethan-1-yl)phenyl, 3-(3-ol-oxetan-3-yl)phenyl, 3-((piperazin-1-yl)methanon-2-yl)phenyl, 3-((morpholin-1-yl)methanon-2-yl)phenyl, 3-((pyrrolidin-1-yl)methanon-2-yl)phenyl, 3-((N-cyclopropyl)amide-2-yl)phenyl, 3-ol-oxetan-3-yl, 2-ol-but-3-en-4-yl and 2-ol-2-trifluoromethyl-(1,1,1-trifluoro)but-3-en-4-yl; and R12 and R14 each independently is hydrogen.
EFFECT: new compounds are obtained that are useful for treatment of an amyloid disease, such as Alzheimer's disease.
11 cl, 2 tbl, 7 dwg
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
SELECTIVE GLYCOSIDASE INHIBITORS AND THEIR APPLICATION | 2012 |
|
RU2625308C2 |
PYRROLE AND PYRAZOLE DAAO INHIBITORS | 2004 |
|
RU2361862C2 |
PYRIMIDINES AND THEIR OPTIONS, AND THEIR APPLICATION | 2017 |
|
RU2760733C2 |
ANTICANCER DIHYDROPYRAN-3-ONE COMPOUNDS | 2007 |
|
RU2444519C2 |
ANTITUMOUR COMPOUNDS | 2008 |
|
RU2493147C2 |
SULFONAMIDE PERI-SUBSTITUTED BICYCLES FOR TREATMENT OF OCCLUSIVE AFFECTION OF ARTERIES | 2005 |
|
RU2403240C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
THIOHYDANTOIN DERIVATIVES USEFUL AS ANDROGEN RECEPTOR ANTAGONISTS | 2012 |
|
RU2598854C2 |
Authors
Dates
2018-01-17—Published
2013-08-22—Filed